A new dog-vaccination and population-management programme in rural Zimbabwe shows why rabies prevention is also an operating question: reaching animals consistently, sustaining coverage and linking animal-health work to community services.

Boehringer Ingelheim, AWARE Germany and AWARE Trust Zimbabwe announced on 23 September a multi-year Stop Rabies project in Tsholotsho District. The programme will combine dog vaccination, population management and education for children through AWARE's veterinary hub and mobile teams. The partners aim to vaccinate about 15,000 dogs a year, reaching estimated coverage of more than 90% of the local dog population, and to provide free sterilisation for at least 1,200 dogs annually.

The design is deliberately broader than a one-off vaccination campaign. Its operating model combines recurring outreach with local veterinary infrastructure and education, seeking to reduce both disease risk and the conditions that make control harder to sustain. Boehringer Ingelheim notes that more than 99% of human rabies cases originate from infected dogs; the company and its partners position canine vaccination as the most effective route to interrupting the risk at source.

For animal-health suppliers and service providers, the project underlines the value of delivery systems around a biological intervention. Vaccine availability is necessary, but cold-chain execution, community confidence, mobile capacity, population management and follow-up determine whether coverage persists. Those are also the elements that turn a dose-based intervention into an investable, measurable disease-control programme.

The initiative is based in one of Zimbabwe's remote and poorest rural areas, where the human and animal-health consequences of rabies can be especially severe. In addition to protecting dogs and people, the partnership says it will support community wellbeing, livelihoods and wildlife conservation. The stated annual targets make its progress more readily assessable than general awareness commitments.

This remains a prevention programme rather than a commercial product launch. Yet it signals an increasingly important part of animal-health strategy: linking veterinary medicines, field delivery and One Health outcomes in regions where disease control depends as much on access and continuity as on scientific capability.

For more information: Boehringer Ingelheim